Acute Intermittent Hypoxia in Traumatic Brain Injury
Launched by SHIRLEY RYAN ABILITYLAB · May 12, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new approach to help people who have suffered a mild to moderate traumatic brain injury (TBI). The researchers are studying a technique called Acute Intermittent Hypoxia (AIH), which involves briefly lowering the amount of oxygen inhaled. The goal is to see if this method is safe for TBI survivors and whether it might improve their memory, thinking skills, and movement. Participants will be closely monitored throughout the study to ensure their safety.
To be eligible for this trial, individuals must be between 18 and 65 years old and have experienced a first-time mild to moderate TBI, as confirmed by medical records. Participants should be able to communicate in English and understand the study details, as well as have someone to assist them after visits. However, those with certain medical conditions, such as severe lung diseases or significant heart problems, cannot participate. If you or a loved one is interested in this study, it could provide valuable insights into new ways to support recovery after a brain injury.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18-65 years
- • A first time, mild to moderate traumatic brain injury (TBI) confirmed by medical records
- • When available, a Glasgow Coma Scale score between 9-15
- • Able to use a keyboard
- • Able to understand and communicate in English
- • Able to consent independently
- • Able to leave a research visit with a companion/group transportation
- • Women of child-bearing age must be comfortable confirming a negative pregnancy prior to participating in the study
- • Not involved in any other research intervention study testing neurobehavioral functioning
- Exclusion Criteria:
- • Other neurological diagnoses or a diagnosis of severe psychiatric disorder (e.g., psychosis) or a reported childhood learning disability
- • Severe aphasia, preventing a participant from understanding the protocol and consent form
- • Pre-existing hypoxic pulmonary disease
- • Severe hypertension (\>160/100)
- • Medically documented history of obstructive lung diseases \[e.g., Chronic obstructive pulmonary disease (COPD) or significant asthma\]
- • Ischemic cardiac disease
- • Ineligible to undergo MRI or TMS
About Shirley Ryan Abilitylab
Shirley Ryan AbilityLab is a leading research and rehabilitation institute dedicated to advancing the science of physical medicine and rehabilitation. Based in Chicago, Illinois, the organization integrates clinical care, research, and education to enhance the quality of life for individuals with disabilities and chronic conditions. Known for its innovative approach, Shirley Ryan AbilityLab conducts clinical trials that aim to develop and evaluate cutting-edge therapies and technologies, fostering a collaborative environment that bridges the gap between laboratory research and patient care. Through its commitment to excellence, the institute strives to empower patients and improve outcomes in rehabilitation medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Jordan Grafman, PhD
Principal Investigator
Shirley Ryan AbilityLab
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials